SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The CD38 cell surface antigen is expressed in diverse hematologic malignancies including multiple myeloma, B-cell non-Hodgkin lymphoma (NHL), B-cell chronic lymphocytic leukemia, B-cell acute lymphoblastic leukemia (ALL), and T-cell ALL. Here, we assessed the antitumor activity of the anti-CD38 antibody SAR650984.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin. Cancer Res.

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1078-0432

ISSN (Print): 1078-0432

Publication date (Electronic): Sep 1 2014

Volume: 20

Issue: 17

Affiliations

[1 ] Research and Development, ImmunoGen, Inc., Waltham, Massachusetts. jutta.deckert@immunogen.com.

[2 ] Oncology Business Division, Sanofi R&D, Vitry-sur-Seine, France.

[3 ] Research and Development, ImmunoGen, Inc., Waltham, Massachusetts.

[4 ] SCP LGCR/Structure Design & Informatics/Structural Biology, Sanofi R&D, Vitry-sur-Seine, France.

[5 ] Biorealization/Operations and Protein Tools, Sanofi R&D, Vitry-sur-Seine, France.

[6 ] Hematology Laboratory, Hospices Civils de Lyon, Pierre Bénite, France and CRCL, INSERM 1052-CNRS 5286, Lyon, France.

Article

Publisher Item ID: 1078-0432.CCR-14-0695

DOI: 10.1158/1078-0432.CCR-14-0695

PubMed ID: 24987056

SO-VID: 9f03b200-e03a-40f9-acbf-fa578ca3d2f3

History

Data availability:

Comments

Comment on this article

scite_

Cited by 133

See all cited by